Overview

Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness

Status:
Withdrawn
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of moderate to severe nocturia in patients with overactive bladder and who do not have non-urologic causes of nocturia.
Phase:
Phase 4
Details
Lead Sponsor:
Cognitive Research Corporation
Collaborator:
Novartis Pharmaceuticals
Treatments:
Darifenacin